Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Queensland Health
Cerilliant
UBS
Accenture
Healthtrust
US Army
Covington
US Department of Justice
Argus Health

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Patent Claims: 1. A process for the preparation of a compound of formula (I): ##STR14## in which n is 1 to 20; R.sup.1 is hydrogen, C.sub.1-6 alkyl or hydroxyC.sub.1-6 alkyl; and R.sup.2 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or trifluoromethyl, which process comprises coupling a compound of formula (II): ##STR15## in which n and R.sup.2 are as defined in formula (I) and R.sup.3 is halogen with a compound of formula (III): ##STR16## in which R.sup.1 is as defined in formula (I) in the presence of palladium catalyst.

2. A process for the preparation of a compound of formula (IA) or a salt or N-oxide thereof: ##STR17## in which: R.sup.1 is hydrogen, benzyl or a group of formula (A): ##STR18## where n is 1 to 20 and R.sup.5 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or trifluoromethyl; m is 0 to 5;

R.sup.8 and R.sup.9 are independently hydrogen, halogen, CO.sub.2 H, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; and

R.sup.10 is a group CR.sup.2 =CR.sup.3 --R.sup.4 or CHR.sup.2 --CHR.sup.3 --R.sup.4 where R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl and R.sup.4 is cyano or CO.sub.2 R.sup.6 where R.sup.6 is hydrogen or C.sub.1-6 alkyl, which process comprises:

coupling a compound of formula (II): ##STR19## in which R.sup.1 is as defined in formula (IA) and R.sup.7 is a leaving group with a compound of formula (III) or a salt thereof: ##STR20## in which R.sup.2, R.sup.3 and R.sup.4 are as defined in formula (IA) in the presence of a palladium catalyst, to give a compound of formula (I): ##STR21## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined in formula (IA), and thereafter: converting the compound of formula (I) into a compound of formula (IA), or converting a compound of formula (IA) into another compound of formula (IA), or forming a pharmaceutically acceptable salt or N-oxide.

3. A process according to claim 1 in which the palladium coupling is carried out in aqueous DMF.

4. A process according to claim 3 in which R.sup.1 is a group of formula (A) where n is 2 to 8.

5. A process according to claim to 4 in which R.sup.4 is CO.sub.2 R.sup.6 where R.sup.6 is hydrogen or C.sub.1-6 alkyl.

6. A process according to claim 5 in which R.sup.5 is methoxy.

7. A process according to claim 1 in which the compound prepared is: n-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}prop enoate, methyl 3-[6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl}propenoate, methyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl}propenoate, t-butyl 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl)propenoate, 3-{6-hydroxymethyl-3-[8(4-methoxyphenyl)octyloxy]pyridin-2-yl }propenoic acid, n-butyl 3-{6-hydroxymethyl-3-(phenylethyloxy)pyridin-2-yl}propenoate, ethyl (3-hydroxy-6-methylpyridin-2-yl)propenoate, ethyl 3-{3-hydroxy-6-hydroxymethylpyridin2-yl}propenoate, ethyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, n-butyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, methyl (3-benzyloxy-6-hydroxymethylpyridin-2-yl)propenoate, and and salts and N-oxides thereof.

8. A process according to claim 2 in which the compound of formula (IA) is 3[2-thia-3-[2-(E-2-carboxyethenyl-3-[8-(4-methoxyphenyl)octyloxy]-6-pyridy l]propyl]benzoic acid, [[1-thia-2-[6-(2-carboxyethyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6-dich lorobenzene, or [[1-thia-2-[6-(E-2-carboxyethenyl)-5-phenylethyloxy-2-pyridyl]]ethyl]-2,6- dichlorobenzene, or pharmaceutically acceptable salts or N-oxides thereof.

9. The process of claim 1 wherein the palladium catalyst is palladium (II) catalyst selected from the group consisting of Pd(OAc).sub.2, Pd(OAc).sub.2 /(o-tol).sub.3 P, Pd(OAc).sub.2 / Ph.sub.3 P, Pd(OAc).sub.2 /tri(2-furyl)phosphine, (Ph.sub.3 P).sub.2 PdCl.sub.2, and PdCl.sub.2 /Ph.sub.3 P.

10. The process according to claim 9 wherein the catalyst is bis(triphenylphosphine)palladium dichloride or palladium acetate.

11. The process of claim 2 wherein the palladium catalyst is a palladium (II) catalyst selected from the group consisting of Pd(OAc).sub.2, Pd(OAc).sub.2 /(o-tol).sub.3 P, Pd(OAc).sub.2 /Ph.sub.3 P, Pd(OAc).sub.2 /tri(2-furyl)phosphine, (Ph.sub.3 P).sub.2 PdCl.sub.2, and PdCl.sub.2 /Ph.sub.3 P.

12. The process according to claim 11 wherein the catalyst is bis(triphenylphosphine)palladium dichloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Merck
AstraZeneca
Dow
Moodys
Fish and Richardson
Mallinckrodt
Daiichi Sankyo
Deloitte
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot